Survodutide (BI 456906) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

Survodutide (BI 456906) is a synthetic 29-amino-acid peptide designed as a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It incorporates structural modifications to the human glucagon sequence, including a non-coded amino acid (1-aminocyclobutane-1-carboxylic acid) at position 2 to enhance proteolytic stability and a glycine-serine linker at position 24 with a C18 fatty acid moiety to prolong half-life through albumin binding. In vitro assays demonstrate that BI 456906 acts as a potent agonist at both receptors, with functional potencies in the nanomolar range for human GCGR and GLP-1R. The peptide exhibits balanced dual receptor engagement, as confirmed in cellular models and transgenic reporter systems, where it simultaneously activates signaling pathways in tissues expressing these receptors.

This peptide is administered via subcutaneous injection and exhibits a long-acting profile. Its dual receptor engagement enables synergistic mechanisms that influence metabolic pathways, including regulation of insulin and glucagon secretion, inhibition of food intake, and modulation of gastric emptying.

• Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hamprecht D, Neubauer H, Augustin R. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022 Dec;66:101633. doi: 10.1016/j.molmet.2022.101633. Epub 2022 Nov 7. PMID: 36356832; PMCID: PMC9679702.
• Awad AA, Abdrabou Abouelmagd A, Mohammed F, Elettreby AM, Mahmoud Marey M, Aldemerdash MA, Soliman SM, Belal MM, Abosheaishaa H. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025 Apr 1;38(4):514-522. doi: 10.1080/08998280.2025.2480512. PMID: 40557198; PMCID: PMC12184113.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.